title: Use of statins in patients with chronic hepatitis C.
abstract: Hepatitis C is a leading cause of liver failure and transplantation in the United States and a major public health issue. Studies have shown that patients with hepatitis C are at an increased risk of cardiovascular disease, which make statins of particular benefit in this patient population. However, the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) lists active or chronic liver disease as an absolute contraindication to statin therapy. The available literature regarding the safety of statins in this patient population is limited, but has not shown clinically significant differences in aminotransferase elevations or evidence of hepatotoxicity in patients with hepatitis C who have received statins versus those who have not. Statins should continue to be avoided in advanced end-stage liver disease, as there is a lack of safety data in these patients and drug metabolism would be severely compromised. Treatment with statins can be used in those with chronic, stable hepatitis C with elevated cardiac risk or a previous cardiac event.
authors.affiliation: Department of Pharmacy Practice, Auburn University Harrison School of Pharmacy, Huntsville, AL, USA.
authors.forename: Miranda R
authors.initials: MR
authors.lastname: Andrus
authors.forename: Jessica
authors.initials: J
authors.lastname: East
mesh_terms: D000328:Adult; D002318:Cardiovascular Diseases / Q000517:prevention & control; D000075202:Contraindications; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D008099:Liver / Q000187:drug effects; D008111:Liver Function Tests; D017035:Pravastatin / Q000009:adverse effects / Q000627:therapeutic use; D000637:Transaminases / Q000097:blood
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000637:Transaminases; D017035:Pravastatin